Category: ipo

Orpheus has launched a $6 million initial public offering to kick-start exploration and provide funds for it to chase high-grade sandstone or sediment-hosted and unconformity (hard rock) deposits.

Portfolio of assets

Argonaut has compiled a portfolio of assets within Orpheus and its wholly-owned subsidiary Trachre through direct application as well as corporate transactions with tenement holders.

It includes early-stage projects at Frome/Erudina and Cummins (in South Australia) and Mount Douglas (Northern Territory) and new applications at Ranger-North East (30 kilometers from the decommissioned Ranger uranium mine), T-Bone (the broader area containing at least 13 uranium deposits and 15 occurrences) and Woolner.

The project generation initiative will focus on areas which have seen limited exploration since Australia’s uranium boom of the 1970s, with Orpheus targeting paleochannel and unconformity uranium deposits that are amenable to simple and economic extraction methods.

Orpheus said an opportunity exists to achieve “science-led exploration success” by leveraging new geophysical datasets in terrains which have lacked modern, systematic uranium exploration.

Uranium production

Last year, South Australia and the Northern Territory were responsible for the production of 4,192 tons of uranium, or approximately 8.7% of total world output.

Orpheus aims to capitalize on this success, led by an executive team with experience in the application of advanced techniques for uranium exploration and a track record of financing and developing resource projects around the world.

Underpinning the company’s strategy is a forecast increase in mid to long-term global demand for uranium in an environment where supply from stable jurisdictions (such as Australia) is currently in structural decline.

The World Nuclear Association has predicted demand will jump 27% from now until 2030 and a 38% from 2030 to 2040, with this demand expected to come mostly from the US, Europe or North Asia.

These regions use uranium in the production of zero-emissions power (meaning they do not directly output carbon dioxide during electricity production) and are considered to be viable and safe options for nuclear generation to meet increasing energy needs.

Company Profile

The company, which is a spin-out of Argonaut Resources (ASX: ARE), will also have a significant project generation budget with the aim to expand and build its pipeline.

Orpheus’ IPO will be based on the issue of a minimum 30 million shares at $0.20 each and will comprise a $3 million priority offer for Argonaut shareholders and a $3 million broker firm and general public offer. Argonaut will retain a 26.9% interest following completion of the offer. The offer is being led by Adelaide based broker Taylor Collison and Becketts Lawyers. Orpheus is expected to list on the ASX before month end using the ticker code ‘ORP’.

DISCLAIMER for General Advice: (This document is for general advice only).

This document is provided by Laverne Securities Pty Ltd T/as Investor Desk. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.

The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require.  The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.

The material in this document has been obtained from sources believed to be true but neither Investor Desk and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Investor Desk and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.

Investor Desk and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Investor Desk and Banyan Tree do and seek to do, business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.

Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Investor Desk and Banyan Tree, its associates, officers, directors, employees, and agents.  Except for any liability which cannot be excluded, Investor Desk and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material.  Recipients of this document agree in advance that Investor Desk and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Investor Desk and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and is not liable for any unintentional errors in the document.

The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Investor Desk and Banyan Tree.

Radiopharm Theranostics Limited issued 83.33 million shares at an offer price of AU$0.60 a piece, giving a market capitalisation of AU$152 million at the issue price.

The Offer comprises: 

(a) the Broker Firm Offer, which is available to Australian resident retail clients of Brokers who have been assigned a firm allocation of Shares by their Broker.

(b) the Institutional Offer, which is an invitation to Institutional Investors in Australia and a number of other eligible jurisdictions to apply for Shares; and 

(c) the Chairman’s List Offer, which is an invitation to selected Australian investors who have received an invitation from the Chairman or the Company to apply for Shares.

Use of funds

 (a) make payments under the Licence Agreements 

 (b) conduct research and development into other cancer targets

 (c) provide working capital; and 

 (d) set up commercial and academic collaborations.

Important dates

Events	Dates
Prospectus date	Thursday, 14 October 2021
Offer opens	Friday, 22 October 2021
Offer closes	Friday, 5 November 2021
Anticipated date of allotment	Tuesday, 16 November 2021
Shareholding statements expected to be dispatched	Friday, 19 November 2021
Anticipated commencement of ASX trading	Thursday, 25 November 2021

Subscription Status:  The shares of  Radiopharm Theranostics Limited  were oversubscribed.

Company Profile:

Formed in February 2021, the homegrown health care company focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. The Company aims to become an industry leader in the development of radiopharmaceutical products, targeting some of the largest markets in cancer.

The Company has a balanced portfolio of four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development, from some of the world’s leading universities and institutes such as Imperial College London and Memorial Sloan Kettering.

The portfolio comprises five Phase 2 clinical trials and two Phase 1 trials, which are underway along with five Phase 1 trials, which have been wrapped up across hospitals and medical centres globally. The clinical trials target a range of cancers including that of breast, lung, kidney, head & neck, pancreatic and brain.

( Source:  https://www.radiopharmtheranostics.com/)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Cobram Estate debuted on the ASX on Wednesday in a compliance listing in which it did not raise new capital but transformed from an unlisted public company with 705 shareholders to a publicly traded company in full view of the public. In its first hour on the ASX, the firm traded between $1.82 and $1.89 a share, giving it a market capitalisation of $706 million at the low end.

The organization’s chairman and co-founder, Rob McGavin, said it was satisfying to have established a corporation worth more than $700 million, but the group is now focused on long-term strategic decisions.

With a market capitalization of $700 million, it is almost twice as valuable as department store chain Myer, a household name that has struggled to keep up with online shopping and the epidemic. Cobram Estate, Australia’s No. 1 extra virgin olive oil and a huge seller at Woolworths and Coles, and Red Island, a more value-oriented brand, are the two prominent brands.

Cobram Estate’s Total Production 

Mr McGavin said that during the epidemic, sales were boosted by frequent capital city lockdowns, which drove many households to look more thoroughly at the sources of items used in recipes. Cobram Estate employs 172 employees, each of whom received 500 free shares as part of the company’s ASX IPO. Cobram Estate grows 2.4 million olive trees on 6854 hectares of farmland in central Victoria, accounting for 71% of Australia’s total olive oil production.

A few weeks ago, stockbrokers tested the appetite of potential investors with a $2 issue price, but found little institutional interest at that level. The board of directors opted to forego any capital offering and instead pursue a compliance listing.

According to the prospectus, Cobram Estate’s revenue for the year ended June 30 is estimated to be $211 million, with a net profit of $33.6 million. Because of the unique characteristics of the olive producing sector, where trees only produce one large crop every two years, the company will need to conduct a substantial education drive for new shareholders.

The harvest in 2021, which lasted from late April to June, was one of the large crop years, implying that next year’s crop will be “light”. The harvest in 2021 was 16.05 million litres, which was 7% higher than expected.

Company Profile 

COBRAM ESTATE PTY LTD is located in DOCKLANDS, VICTORIA, Australia and is part of the Fruit and Tree Nut Farming Industry. COBRAM ESTATE PTY LTD has 120 employees at this location and generates $4.80 million in sales (USD). (Employees figure is estimated, Sales figure is modelled). There are 10 companies in the COBRAM ESTATE PTY LTD corporate family.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

which is 60% greater than the company’s prospectus offer price of 20 cents. Openn Negotiation is a real estate technology firm. Its cloud-based Openn platform enables real estate bids to take place in real time and transparent private treaty offers to be submitted. So far, the platform has over $2 billion in property sales which is used by over 3,300 real estate agents across Australia and New Zealand.

On the ASX, the real estate technology stock is off to a strong start

The company had roughly 191.7 million shares outstanding at the time of its listing. At 20 cents per share, Openn’s market capitalisation is expected to be around $38 million. Openn Negotiation has a market capitalisation of around $57.5 million at its current share price.

The company anticipated that its IPO would raise $9 million before expenses.The funds will be used by Openn Negotiation to expand its business in Australia and New Zealand, as well as to assess the market in the United States. It intends to enter the American market in the future.

Because it did not believe it could prepare reliable forecasts, the company did not include financial guidance in its offer document. The company’s full-year earnings for the 2020 fiscal year were $851,402 with a loss of around $1.2 million before taxes. Openn also had $668,979 in assets and $448,975 in debt.

Currently, fees charged to upload properties onto the platform account for 90% of Openn Negotiation’s revenue. An agent must pay $500 to upload a property to the Openn platform. It also makes money by training real estate agents to use the platform, a service that costs $135.45 per agent.

Company Profile

The need for a better way of doing things prompted the creation of Openn Negotiation, as it did many other innovative developments.In 2016, our Founders, Peter Gibbons, a technology developer, and Peter Clements and Brad Glover, leading Western Australian real estate brokers, began collecting years of input from sellers, purchasers, and agents on the problems of the present sales process.

Source : fool.com

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.